References

1. Y Lin,Z Sun (2010). Current views on type 2 diabetes.
2. A Astrup,N Finer (2000). Redefining Type 2 diabetes: ‘Diabesity’ or ‘Obesity Dependent Diabetes Mellitus’?.
3. Lalita Khaodhiar,Sue Cummings,Caroline Apovian (2009). Treating diabetes and prediabetes by focusing on obesity management.
4. R Defronzo (2009). From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus.
5. H Pijl (2003). Reduced dopaminergic tone in hypothalamic neural circuits: expression of a ''thrifty''genotype underlying the metabolic syndrome.
6. A Tschoner,J Engl,M Laimer,S Kaser,M Rettenbacher,W Fleischhacker,J Patsch,C Ebenbichler (2007). Metabolic side effects of antipsychotic medication.
7. G Wang,N Volkow,P Thanos (2009). Brain Dopamine Pathways and Obesity.
8. U Pagotto (2009). Where Does Insulin Resistance Start? The brain.
9. Sudarshana Purkayastha,Dongsheng Cai (2013). Neuroinflammatory basis of metabolic syndrome.
10. R Scranton,M Ezrokhi,J Gaziano (2008). Randomized Pilot Study of Cabergoline, a Dopamine Receptor Agonist: Effects on Body Weight and Glucose Tolerance in Obese Adults Diabetes.
11. S Inancli,A Usluogullari,Ustu (2013). Effect of cabergoline on insulin sensitivity, inflammation, and carotid intima media thickness in patients with prolactinoma.
12. Ranganath Muniyappa,Sihoon Lee,Hui Chen,Michael Quon (2008). Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage.
13. S Taghavi,S Fatemi,H Rokni (2012). Cabergoline Effect on Blood Sugar in Type 2 Diabetic Patients with Oral Agent Failure.
14. P Kok,F Roelfsema,M Frolich (2006). Activation of dopamine D2 receptors simultaneously ameliorates various metabolic features of obese women.
15. N Merican,N Sukor,A Razali (2013). The Effects of Short Term Cabergoline Therapy on Disease Activity and Metabolic Parameters in Acromegaly.
16. Alessandro Ciresi,Marco Amato,Valentina Guarnotta,Flavia Lo Castro,Carla Giordano (2013). Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels.
17. Krysiak Rand Okopien,B (2014). Different Effects of Cabergoline and Bromocriptine on Metabolic and Cardiovascular Risk Factors in Patients with Elevated Prolactin Levels.
18. A Cincotta,A Meier,M Cincotta (1999). Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: A new approach in the treatment of diabetes.
19. A Ghosh,N Sengupta,P Sahana (2014). Efficacy and safety of add on therapy of bromocriptine with metformin in Indian patients with type 2 diabetes mellitus: A randomized open labeled phase IV clinical trial.
20. K Bina,A Cincotta (2000). Figure 2. Glucose-lowering therapy used by patients with primary hyperparathyroidism and diabetes mellitus type 2 (people): metformin — 13; dipeptidyl-peptidase 4 inhibitors (DPP4i) — 2; combination of metformin and DPP4i — 5; combination of metformin and glucagon-like peptide 1 receptor agonists — 1; combination of metformin and sodium-glucose transporter 2 inhibitors (SGLT2i) — 2; sulfonylurea compounds — 1; combination of metformin and sulfonylurea — 2; комбинация combination of metformin, sulfonylurea and SGLT2i — 1; combination of metformin, sulfonylurea and long-acting insulin — 1; combination of metformin, SGLT2i and short-acting insulin — 2; intensive insulin therapy — 4..
21. Yin Liang,Maggie Lubkin,Hong Sheng,Piotrw. Scislowski,Anthony Cincotta (1998). Dopamine agonist treatment ameliorates hyperglycemia, hyperlipidemia, and the elevated basal insulin release from islets of ob/ob mice.
22. R Turner,A Rudenski,D Matthews (1990). Application of structural model of glucoseinsulin relations to assess beta-cell function and insulin sensitivity.
23. Tara Wallace,Jonathan Levy,David Matthews (2004). Use and Abuse of HOMA Modeling.
24. K Berinder,T Nystrom,C Hoybye (2011). Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy.
25. Dos Santos Silva,C Barbosa,F Lima,G (2011). BMI and Metabolic Profile in Patients with Prolactinoma before and After Treatment with Dopamine Agonists.
26. Michael Ezrokhi,Shuqin Luo,Yelena Trubitsyna,Anthony H. Cincotta (2012). Weighted Effects of Bromocriptine Treatment on Glucose Homeostasis during Hyperglycemic versus Euglycemic Clamp Conditions in Insulin Resistant Hamsters: Bromocriptine as a Unique Postprandial Insulin Sensitizer.
27. Futoshi Anan,Naohiko Takahashi,Mikiko Nakagawa,Tatsuhiko Ooie,Tetsunori Saikawa,Hironobu Yoshimatsu (2005). High-sensitivity C-reactive protein is associated with insulin resistance and cardiovascular autonomic dysfunction in type 2 diabetic patients.
28. B Corkey (2012). Hyperinsulinemia: Cause or Consequence?.
29. A Ustione,D Piston,P Harris (2013). A Mini review: Dopaminergic regulation of Insulin Secretion from the Pancreatic Islet.
30. M Sowell,N Mukhopadhyay,P Cavazzoni (2002). Hyperglycemic Clamp Assessment of Insulin Secretory Responses in Normal Subjects Treated with Olanzapine, Risperidone, or Placebo.
31. Isabel García-Tornadú,Ana Ornstein,Astrid Chamson-Reig,Michael Wheeler,David Hill,Edith Arany,Marcelo Rubinstein,Damasia Becu-Villalobos (2010). Disruption of the Dopamine D2 Receptor Impairs Insulin Secretion and Causes Glucose Intolerance.
32. R Brown,Ki Rother,R Pivonello,De Martino,C Cappabianca,P (2008). The Medical Treatment of Cushing's disease: Effectiveness of Chronic Treatment with the Dopamine Agonist Cabergoline in Patients Unsuccessfully Treated by Surgery.
33. Mariano Galdiero,Renata Auriemma,Pasquale Vitale,Fabio Calzo,Ciro Salzano,Lucia Ferreri,Federica Cariati,Giorgio Coppola,Annamaria Colao,Rosario Pivonello (2014). Effect of chronic treatment with cabergoline and testosterone replacement on metabolic parameters in male patients with prolactinomas and hypogonadism.
34. K Sung,G Reaven,Kim Sh (2010). Utility of Homeostasis Model Assessment of B-Cell Function in Predicting Diabetes in 12,924 Healthy Koreans.